Calquence Approval History
FDA Approved: Yes (First approved October 31, 2017)
Brand name: Calquence
Generic name: acalabrutinib
Dosage form: Capsules
Treatment for: Mantle Cell Lymphoma
Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL).
Development History and FDA Approval Process for Calquence
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.